The Corona Remedies Ltd. IPO is all set to hit the market on Monday, December 8, drawing attention from retail and institutional investors alike. The Ahmedabad-based pharmaceutical company is gearing up to raise Rs 655.37 crore through its initial public offering (IPO), which will be a completely offer-for-sale (OFS) of 62 lakh shares.
Corona Remedies has carved a niche in the pharmaceutical sector by developing, manufacturing, and marketing a diverse range of products across multiple therapeutic segments, including women’s health, cardiology, pain management, and urology. With the IPO bidding period approaching, market participants are closely watching grey market trends and investor appetite.
The IPO has been priced in the band of Rs 1,008 to Rs 1,062 per share, positioning it as a mid-cap offering in the pharmaceutical sector. Investors can apply for a minimum lot size of 14 shares, which translates to an investment of approximately Rs 14,112 at the upper price band. Applications can be made in multiples of the minimum lot size, allowing investors to scale their investment based on their appetite and risk profile.
As the IPO opens for subscription, retail investors are expected to play a key role, given the growing participation in pharma IPOs and the steady performance of sector peers in the public markets.
Ahead of the IPO, grey market trends provide a preliminary gauge of market sentiment. While official allotments are yet to begin, investors and brokers in the grey market have shown interest in pre-listing trades of Corona Remedies shares. The Grey Market Premium (GMP), a commonly used indicator for IPO sentiment, suggests a positive listing, signalling that investors are optimistic about the stock’s debut performance.
Although precise GMP figures fluctuate daily, market observers indicate healthy demand from both retail and institutional participants, reflecting confidence in the company’s business model and growth prospects. Positive GMP trends generally suggest potential listing gains for early investors, but these gains are subject to market conditions on listing day and actual subscription levels.
Also Read: JSW Steel Targets Major Debt Reduction After Selling 50% BPSL Stake to Japan’s JFE Steel
Corona Remedies Ltd., headquartered in Ahmedabad, operates across multiple therapeutic segments, focusing on areas such as:
Women’s health
Cardiology
Pain management
Urology
The company is engaged in the research, development, and marketing of pharmaceutical products, catering to a growing domestic and international market. Its diversified product portfolio positions it to benefit from increasing demand for healthcare solutions in India.
The IPO proceeds, though entirely an OFS, indicate the company’s intent to provide liquidity to existing shareholders while attracting new market participants. Such offerings are also often viewed as a signal of shareholder confidence in the company’s valuation and market potential.
With the IPO opening on December 8, investors can submit bids for the minimum lot size of 14 shares, amounting to Rs 14,112 at the upper price band. Retail participation is expected to be robust due to the company’s presence in the pharmaceutical sector, which has historically witnessed sustained demand.
Institutional investors are also likely to participate actively, considering the company’s established market presence and diversified therapeutic portfolio. The subscription from Non-Institutional Investors (NIIs) and Qualified Institutional Buyers (QIBs) will determine the overall subscription level, which will influence the final allotment and listing performance.
The pharmaceutical sector continues to attract investors due to its resilient growth prospects and defensive characteristics. Companies with diversified portfolios and strong distribution networks, like Corona Remedies, are particularly appealing to investors seeking long-term growth and stable returns.
The IPO is likely to enhance market visibility for the company and provide a benchmark for other mid-sized pharmaceutical firms considering a public listing. Additionally, a successful debut can serve as a confidence booster for investors in the sector, especially retail participants looking for long-term investment opportunities.
The Corona Remedies IPO, opening on December 8, is poised to capture investor attention with its Rs 655.37 crore OFS, competitive pricing band of Rs 1,008-1,062, and positive grey market signals. With its established footprint in women’s health, cardiology, pain management, and urology, the company presents an attractive opportunity for retail and institutional investors seeking exposure to the pharmaceutical sector.
As market participants await the listing, the IPO’s performance will depend on grey market trends, overall subscription levels, and market conditions on the day of listing. Investors are advised to carefully assess their investment strategy and consult certified financial advisors before participating in the offering.
Disclaimer :
The views, figures, and trends mentioned in this article are based solely on NDTV Profit reporting. Investors should consult certified financial advisors before making any investment decisions.
Click here to explore: Corona Remedies IPO
The IPO market witnessed strong action on Friday as Meesho, Aequs, and Vidya Wires entered…
ITC Hotels witnessed one of its biggest trading sessions in recent months as a massive…
In a major monetary policy move, the Reserve Bank of India (RBI) delivered a 25…
Indian Rupee Weakness Persists, but Analysts See Undervaluation Creating a Long-Term Opportunity The Indian rupee’s…
Sensex Slides from Day’s High as Nifty Ends Below 26,050: Five Key Reasons Behind the…
Cigarette Prices May Edge Higher Under New Excise Bill, but Analysts Expect Only Mild Impact…
This website uses cookies.